Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
Belumosudil 200 mg QD
Belumosudil 200 mg BID
+1 more
Locations
8
United States
City of Hope Site Number : 050
Duarte, California, United States
Stanford Cancer Center Site Number : 108
Stanford, California, United States
Washington University School of Medicine Site Number : 125
St Louis, Missouri, United States
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center Site Number : 132
Pittsburgh, Pennsylvania, United States
South Austin Medical Center Site Number : 091
Austin, Texas, United States
MD Anderson Cancer Center Site Number : 057
Houston, Texas, United States
Start Date
February 23, 2022
Primary Completion Date
June 6, 2024
Completion Date
June 6, 2024
Last Updated
May 2, 2025
NCT07124078
NCT03640481
NCT04200365
NCT05121142
NCT03689894
NCT05348096
Lead Sponsor
Kadmon, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions